Chinese scientists have successfully developed an integrated platform named SPARK-seq, which can simultaneously realize the discovery of cell membrane surface biomarkers and the acquisition of targeted aptamer probes at the single-cell resolution.
Compared with traditional methods, the screening efficiency of SPARK-seq has been improved by more than 100 times, and it can accurately lock potential cancer biomarkers and therapeutic targets.
The Hefei Institutes of Physical Science of CAS, in collaboration with Huazhong University of Science and Technology, Aix-Marseille University in France, and other institutions, has achieved important results in experiments on the Experimental Advanced Superconducting Tokamak (EAST), the country’s "artificial sun" fusion device. Based on the self-organization theory of boundary plasma-wall interactions, the research team has experimentally confirmed the existence of the tokamak density free regime through physical experiments.
This work provides crucial clues for understanding the density limit and offers important physical basis for the high-density operation of tokamak devices.
In 2025, China’s three major manned submersibles completed a total of 321 dives in practice. Among them, the Jiaolong conducted 94 dives, the Deep Sea Warrior 109 dives, and the Fendouzhe 118 dives. As the submersible with the most dives in 2025, the Fendouzhe not only realized the normalization of China’s manned deep-sea dives to the full ocean depth of 10,000 meters, but also successfully unlocked the Arctic’s ice-locked seas, expanding the footprint of China’s manned deep-sea exploration from the full ocean depth to the entire global ocean area.
Yifan Pharmaceutical has signed an Exclusive Agreement with Sundea Pharma and Tianjin Sundea. Pursuant to the agreement, Sundea Pharma grants Chipont Pharma the rights to its independently developed drug ACT001, with the cooperation scope covering mainland China, South Korea, Southeast Asia and other regions, and the cooperation field focusing on small cell lung cancer with brain metastasis.
Black Sesame Intelligence announced that its high-performance intelligent driving chip, the Huashan A2000, has successfully passed the reviews conducted by the U.S. Department of Commerce and the U.S. Department of Defense, obtaining approval for global sales. Based on a 7nm manufacturing process, the chip delivers performance comparable to the world's top-tier products. It supports multi-precision computing and a highly efficient development toolchain, providing core computing power for the commercialization of high-level intelligent driving systems.
